Marshall Wace, LLP Myovant Sciences Ltd. Transaction History

Marshall Wace, LLP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$24.03 - $27.02 $483,411 - $543,561	20,117 Added 55.75%	56,200 $1.52 Million
Q3 2022 Nov 14, 2022	SELL	$11.6 - $20.44 $6.93 Million - $12.2 Million	-597,222 Reduced 94.3%	36,083 $648,000
Q2 2022 Aug 15, 2022	BUY	$7.78 - $14.69 $4.93 Million - $9.3 Million	633,305 New	633,305 $7.87 Million
Q1 2022 May 16, 2022	SELL	$11.38 - $16.4 $616,716 - $888,765	-54,193 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$14.31 - $23.87 $406,103 - $677,406	28,379 Added 109.94%	54,193 $844,000
Q2 2021 Aug 13, 2021	BUY	$17.07 - $24.56 $440,644 - $633,991	25,814 New	25,814 $588,000
Q1 2021 May 17, 2021	SELL	$20.46 - $25.18 $176,569 - $217,303	-8,630 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$13.8 - $27.62 $119,094 - $238,360	8,630 New	8,630 $238,000
Q3 2020 Nov 16, 2020	SELL	$14.05 - $22.6 $2.33 Million - $3.75 Million	-165,934 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$7.34 - $20.84 $933,464 - $2.65 Million	127,175 Added 328.12%	165,934 $3.42 Million
Q1 2020 May 15, 2020	BUY	$6.55 - $14.76 $253,871 - $572,082	38,759 New	38,759 $293,000
Q4 2019 Feb 14, 2020	SELL	$4.2 - $19.21 $294,911 - $1.35 Million	-70,217 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$5.19 - $9.46 $364,426 - $664,252	70,217 New	70,217 $365,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.